In another study, the knockdown of NEAT1 improved cisplatin response by increasing miR-770-5p and decreasing PARP1, demonstrating a novel treatment target for enhancing the efficacy of cisplatin in ovarian cancer cells 29. This evidence concerns the gene PARP1 and ovarian carcinoma.